Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pui-Kei Wu

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Seminars in Oncology|November 29, 2015
MEK1/2 Inhibitors: Molecular Activity and Resistance MechanismsPui-Kei Wu, Jong-In Park
International Journal of Molecular Sciences|August 6, 2020
Growth Inhibitory Signaling of the Raf/MEK/ERK PathwayPui-Kei Wu, Andrew Becker, Jong-In Park
International Journal of Molecular Sciences|December 24, 2021
eIF5A-Independent Role of DHPS in p21<sup>CIP1</sup> and Cell Fate RegulationAndrew E Becker, Pui-Kei Wu, Jong-In Park
Cancer Letters|January 13, 2021
Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf<sup>V600E</sup> melanoma cellsPui-Kei Wu, Seung-Keun Hong, Jong-In Park
Molecular and Cellular Biology|July 5, 2017
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in <i>KRAS</i> and <i>BRAF</i> Tumor CellsPui-Kei Wu, Seung-Keun Hong, Jong-In Park
Cellular Signalling|October 8, 2017
A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responsesSeung-Keun Hong, Pui-Kei Wu, Jong-In Park
Cancer Biology & Therapy|May 6, 2017
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cellsDmytro Starenki, Seung-Keun Hong, Pui-Kei Wu, et al.
Cellular Signalling|July 13, 2015
ERK1/2 can feedback-regulate cellular MEK1/2 levelsSeung-Keun Hong, Pui-Kei Wu, Mansi Karkhanis, et al.
Cancer Biology & Therapy|October 28, 2016
Suppression of B-Raf<sup>V600E</sup> melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinoneSeung-Keun Hong, Dmytro Starenki, Pui-Kei Wu, et al.
The FEBS Journal|February 3, 2015
Active ERK2 is sufficient to mediate growth arrest and differentiation signalingPui-Kei Wu, Seung-Keun Hong, Seung-Hee Yoon, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Seminars in Oncology|November 29, 2015
MEK1/2 Inhibitors: Molecular Activity and Resistance MechanismsPui-Kei Wu, Jong-In Park
International Journal of Molecular Sciences|August 6, 2020
Growth Inhibitory Signaling of the Raf/MEK/ERK PathwayPui-Kei Wu, Andrew Becker, Jong-In Park
International Journal of Molecular Sciences|December 24, 2021
eIF5A-Independent Role of DHPS in p21<sup>CIP1</sup> and Cell Fate RegulationAndrew E Becker, Pui-Kei Wu, Jong-In Park
Cancer Letters|January 13, 2021
Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf<sup>V600E</sup> melanoma cellsPui-Kei Wu, Seung-Keun Hong, Jong-In Park
Molecular and Cellular Biology|July 5, 2017
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in <i>KRAS</i> and <i>BRAF</i> Tumor CellsPui-Kei Wu, Seung-Keun Hong, Jong-In Park
Cellular Signalling|October 8, 2017
A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responsesSeung-Keun Hong, Pui-Kei Wu, Jong-In Park
Cancer Biology & Therapy|May 6, 2017
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cellsDmytro Starenki, Seung-Keun Hong, Pui-Kei Wu, et al.
Cellular Signalling|July 13, 2015
ERK1/2 can feedback-regulate cellular MEK1/2 levelsSeung-Keun Hong, Pui-Kei Wu, Mansi Karkhanis, et al.
Cancer Biology & Therapy|October 28, 2016
Suppression of B-Raf<sup>V600E</sup> melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinoneSeung-Keun Hong, Dmytro Starenki, Pui-Kei Wu, et al.
The FEBS Journal|February 3, 2015
Active ERK2 is sufficient to mediate growth arrest and differentiation signalingPui-Kei Wu, Seung-Keun Hong, Seung-Hee Yoon, et al.
Pageof 3